Targanta Therapeutics Corporation (NASDAQ: TARG) today announced the presentation of key clinical findings of its lead antibiotic drug candidate, oritavancin, at the combined annual meetings of the 48th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the 46th Infectious Disease Society of America (IDSA), taking place in Washington, DC.

Targanta Therapeutics Corporation (Nasdaq: TARG) today announced initial efficacy and safety results from its Phase 2 clinical study investigating oritavancin at Single or Infrequent Doses for the Treatment of Complicated Skin and Skin Structure Infections (cSSSI), or SIMPLIFI.